Alcohol septal ablation for hypertrophic obstructive cardiomyopathy follow-up and surveillance

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Nehal Eid, M.D.[2]

Follow-up and surveillance

Patients remain at risk for conduction disease, recurrent left ventricular outflow tract obstruction (LVOTO), atrial and ventricular arrhythmias, heart failure progression, and sudden cardiac death (SCD) after alcohol septal ablation (ASA). Successful gradient reduction does not eliminate the underlying hypertrophic cardiomyopathy (HCM); lifelong surveillance is therefore required.

Surveillance schedule

Suggested surveillance after ASA

Time point	Core assessments	Principal objectives
During hospitalization	Continuous telemetry for at least 48–72 hours; serial 12-lead ECG; longer monitoring when new conduction disease or pre-existing bundle branch block is present	Detect complete heart block, ventricular arrhythmias, and evolving conduction abnormalities
Before discharge	Clinical assessment, 12-lead ECG, and transthoracic echocardiography (TTE)	Document initial LVOT gradient, systolic anterior motion, mitral regurgitation, left ventricular function, and absence of ventricular septal defect
3–6 months	Clinical reassessment, 12-lead ECG, and TTE with resting and provocable LVOT gradients	Assess procedural response, septal remodeling, symptoms, residual obstruction, mitral regurgitation, and ventricular function
Every 1–2 years	Clinical review, TTE, 12-lead ECG, 24- to 48-hour ambulatory ECG monitoring, and SCD risk reassessment	Detect recurrent obstruction, progressive ventricular dysfunction, atrial fibrillation, nonsustained ventricular tachycardia, and changes in ICD eligibility
Symptom- or question-triggered	Extended rhythm monitoring; exercise testing or cardiopulmonary exercise testing; exercise or Valsalva echocardiography; TTE or cardiac magnetic resonance imaging (CMR) as appropriate	Evaluate unexplained functional limitation, palpitations, presyncope, syncope, recurrent exertional symptoms, or suspected structural progression
Selected patients every 3–5 years	Contrast-enhanced CMR	Reassess fibrosis, ventricular remodeling, apical aneurysm, or systolic dysfunction when clinically relevant

Immediate postprocedural monitoring

Conduction surveillance

Transient complete heart block (CHB) occurs in a substantial proportion of patients after ASA and usually resolves within 24 hours. Contemporary permanent pacemaker implantation rates are approximately 6.5%–11% at experienced centers, although older series using larger ethanol volumes reported rates as high as 20%.

Continuous telemetry for at least 48–72 hours is appropriate after ASA. Monitoring should be extended when there is pre-existing bundle branch block, new right bundle branch block, transient intraprocedural CHB, or another evolving conduction abnormality.

In a series of 243 patients:

• 86% of initial CHB episodes occurred within 24 hours.
• CHB first presenting after 72 hours occurred in 0.8%.
• Timely discharge may therefore be considered in selected patients without early conduction disturbances, particularly when baseline bundle branch block is absent.

Delayed atrioventricular block remains possible. For patients considered at increased risk, prolonged ambulatory electrocardiographic monitoring may be considered after discharge (Class 2b, C-LD).

Electrophysiologic study may assist risk stratification when new right bundle branch block, transient CHB, or both develop. Measurement of the His–ventricular interval has been evaluated for identifying patients more likely to require permanent pacing, but this strategy is not established for routine use.

Predischarge imaging

TTE before discharge should document:

• Resting LVOT gradient
• Residual systolic anterior motion of the mitral valve
• Severity of mitral regurgitation
• Left ventricular systolic function
• Pericardial effusion
• Ventricular septal defect

Early residual obstruction does not necessarily indicate procedural failure because septal thinning and ventricular remodeling continue after discharge.

Early follow-up at 3–6 months

For patients who have undergone septal reduction therapy, TTE within 3–6 months is recommended to evaluate procedural results (Class 1, B-NR).

The examination should assess:

• Septal thickness and remodeling
• Resting LVOT gradient
• Provocable LVOT gradient with Valsalva or exercise when clinically indicated
• Residual systolic anterior motion and mitral regurgitation
• Left ventricular systolic and diastolic function
• Ventricular septal defect
• Alternative mechanisms of persistent obstruction

ASA-induced remodeling is progressive. Much of the response is apparent by 3 months, but further remodeling may continue for 6–12 months in some patients.

Clinical reassessment should include NYHA functional class, exertional symptoms, syncope or presyncope, palpitations, interval hospitalizations, medication use, and a 12-lead ECG.

Role of cardiac magnetic resonance imaging

Routine CMR solely because ASA was performed is not required. CMR is useful when echocardiography does not adequately define ventricular function, remodeling, fibrosis burden, or the mechanism of persistent or recurrent obstruction.

Late gadolinium enhancement CMR can define the location and extent of the ASA-induced infarct and identify mechanisms of an incomplete response, including an inadequately positioned scar or persistent midventricular obstruction.

Long-term surveillance

After the remodeling phase, surveillance follows the lifelong HCM framework:

• TTE every 1–2 years: Assess wall thickness, chamber dimensions, systolic and diastolic function, recurrent or new LVOTO, and valvular disease.
• 12-lead ECG every 1–2 years: Evaluate evolving conduction disease and atrial or ventricular arrhythmias (Class 1, B-NR).
• Ambulatory ECG monitoring every 1–2 years: Perform 24- to 48-hour monitoring to detect nonsustained ventricular tachycardia and occult atrial fibrillation (Class 1, B-NR).
• Extended monitoring for symptoms: Use extended ambulatory monitoring or event recording for new palpitations, lightheadedness, presyncope, or syncope (Class 1, B-NR).
• Selected CMR every 3–5 years: Consider when reassessment of fibrosis, ventricular remodeling, systolic dysfunction, or apical aneurysm would change management.
• Exercise testing: Use exercise testing or cardiopulmonary exercise testing when objective assessment of functional capacity, symptom–gradient correlation, prognostication, or activity counseling is needed.
• Earlier reassessment: Repeat imaging and rhythm evaluation promptly when symptoms, examination findings, or clinical status change.

When the resting LVOT gradient is below 50 mm Hg but symptoms suggest dynamic obstruction, Valsalva or exercise echocardiography should be used to assess provocable LVOTO.

Residual or recurrent obstruction

Residual or recurrent LVOTO requiring further septal reduction therapy occurs in approximately 10%–20% of patients after ASA. Detailed outcome estimates and predictors are addressed in the outcomes microchapter.

Surveillance should focus on the return of clinically significant resting or provocable obstruction, recurrent systolic anterior motion-mediated mitral regurgitation, persistent or recurrent exertional symptoms, ventricular dysfunction, and structural abnormalities unlikely to respond to repeat ASA.

Repeat intervention should generally be deferred until at least 3–6 months after ASA to permit remodeling, unless severe residual obstruction with refractory symptoms requires earlier reassessment by an experienced HCM team.

Arrhythmia surveillance

Sudden cardiac death risk reassessment

SCD risk should be reassessed at least every 1–2 years and whenever clinical status changes. Major risk factors to reassess include:

• Previous cardiac arrest or sustained ventricular tachycardia
• HCM-related SCD in a first-degree relative aged 50 years or younger
• Maximum left ventricular wall thickness of at least 30 mm
• Suspected arrhythmic syncope
• Left ventricular apical aneurysm with scar or late gadolinium enhancement
• Left ventricular ejection fraction below 50%

Nonsustained ventricular tachycardia on ambulatory monitoring and extensive late gadolinium enhancement may modify ICD decision-making when conventional major risk factors are absent.

The ESC HCM Risk-SCD model has been validated in 844 patients after ASA but demonstrated modest discrimination (C-statistic 0.61). Prior ASA and its induced scar may serve as risk arbitrators in clinically ambiguous cases, but ICD decisions should remain based on comprehensive HCM risk assessment.

Implantable cardiac monitors

Routine implantable cardiac monitor placement after ASA is not guideline-recommended. In a prospective study of 56 patients, continuous monitoring detected a cumulative arrhythmic event rate of 71% at 18 months, including atrial fibrillation in 37% and CHB in 19%. Detected atrial fibrillation and CHB led to anticoagulation and permanent pacemaker implantation, respectively.

These data support selective use in patients with unexplained syncope, recurrent symptoms, or high concern for intermittent arrhythmia, but do not establish routine implantation.

Atrial fibrillation surveillance and anticoagulation

De novo atrial fibrillation occurred in approximately 21% of patients after septal reduction therapy in the SHARE Registry. Because the registry included both ASA and myectomy, this estimate should not be interpreted as ASA-specific.

• Patients at increased AF risk should undergo extended ambulatory monitoring at initial evaluation and during periodic follow-up.
• In lower-risk patients, periodic extended monitoring every 1–2 years may be considered to detect asymptomatic paroxysmal AF.

The following episode-duration thresholds are HCM-specific recommendations from the 2024 AHA/ACC HCM guideline and should not be generalized to device-detected atrial fibrillation in patients without HCM.

Anticoagulation after detection of atrial fibrillation in HCM

Rhythm finding	Recommendation	Class and level of evidence
Clinical atrial fibrillation	Begin anticoagulation with a direct oral anticoagulant as first-line therapy or a vitamin K antagonist as second-line therapy, independent of CHA₂DS₂-VASc score.	Class 1, B-NR
Device-detected or subclinical atrial fibrillation lasting more than 24 hours	Anticoagulation is recommended, independent of CHA₂DS₂-VASc score.	Class 1, C-LD
Device-detected or subclinical atrial fibrillation lasting 5 minutes to 24 hours	Anticoagulation can be beneficial after individualized assessment.	Class 2a, C-LD

The CHA₂DS₂-VASc score should not be used to withhold anticoagulation in a patient with HCM and qualifying atrial fibrillation.

Exercise and activity surveillance

Exercise recommendations after ASA continue to follow the general HCM framework and should be individualized according to residual obstruction, arrhythmia burden, ventricular function, and SCD risk:

• Mild-to-moderate recreational exercise is beneficial (Class 1, B-R).
• Vigorous recreational activity is reasonable after annual comprehensive evaluation and shared decision-making with an HCM expert (Class 2a, B-NR).
• Competitive sports may be considered after expert evaluation and shared decision-making (Class 2b, B-NR).
• Universal restriction from vigorous physical activity is not beneficial for most patients with HCM (Class 3: No Benefit).
• ICD implantation solely to permit participation in competitive sports should not be performed (Class 3: Harm).

Exercise testing or cardiopulmonary exercise testing may objectively document functional improvement after ASA and clarify discordance between reported symptoms, residual obstruction, and measured exercise capacity. Improved exercise tolerance does not eliminate the need for periodic assessment of obstruction and arrhythmic risk.

Device follow-up

When a permanent pacemaker or ICD has been implanted, routine device interrogation should be integrated into the surveillance plan. Follow-up may include in-person interrogation every 6–12 months or remote monitoring, with earlier review for symptoms, device alerts, suspected lead dysfunction, arrhythmia detection, or changes in pacing burden.

Device review should assess:

• Battery and lead function
• Ventricular pacing burden
• Stored atrial and ventricular arrhythmias
• Episodes of delayed atrioventricular block
• Appropriate and inappropriate ICD therapies
• Need for changes in device programming

Pregnancy and reproductive counseling

Women of childbearing potential should receive preconception counseling regarding HCM-related pregnancy risk, medication review, and the need for coordinated surveillance during pregnancy. Prior ASA does not eliminate the hemodynamic and arrhythmic considerations associated with HCM. Pregnancy management should be coordinated with clinicians experienced in HCM and maternal cardiovascular disease.

Coordination of long-term care

Follow-up should be coordinated between the interventional HCM center and the referring cardiologist. The shared plan should specify:

• Timing and responsibility for TTE, ECG, ambulatory monitoring, and clinical reassessment
• Criteria for expedited HCM-center review
• Responsibility for SCD risk reassessment and ICD referral
• Management of newly detected atrial fibrillation
• Evaluation of residual or recurrent obstruction
• Device interrogation when a pacemaker or ICD is present

Patients should be informed that ASA treats obstruction but does not cure the underlying cardiomyopathy; surveillance remains lifelong.

Follow-up visits should also confirm that first-degree relatives have been offered clinical screening and, where appropriate, genetic counseling in accordance with HCM guidelines.

Evidence limitations

• The optimal duration of inpatient telemetry is not standardized and varies from approximately 48 hours to 7 days according to conduction risk and institutional practice.
• Routine implantable cardiac monitoring after ASA is not guideline-endorsed.
• The effect of ASA-induced scar burden on ICD selection is not clearly distinguished from disease-related fibrosis in current guidelines.
• The HCM Risk-SCD model has only modest discrimination after ASA.
• The optimal frequency and modality of AF screening after ASA are extrapolated largely from general HCM guidance rather than ASA-specific trials.
• Specific surveillance during pregnancy, device follow-up, family screening, and exercise testing primarily follows the broader HCM framework rather than ASA-specific evidence.